Mesenchymal stem cells (MSCs) are a subset of non-hematopoietic adult stem cells that originate from the mesoderm. MSCs are able to self-renew and differentiate into multiple cell lineages including not only mesoderm lineages, such as chondrocytes, osteocytes and adipocytes, but also ectodermic cells and endodermic cells. MSCs have shown promise in regenerative medicine including peripheral arterial disease. Although MSCs are present in most tissues including bone marrow and adipose tissue, they are only present at low levels. To harvest sufficient MSCs to manufacture a cellular therapy product it is necessary to expand the number of MSCs in vitro.
Rexgenero’s adipose-derived mesenchymal stem cell product REX-002 has demonstrated some promise in CLI and is currently under development in a phase I/II clinical trial.